FDA Advisors To Determine Need For Post-Marketing Study Of GTC Biotherapeutics’ ATryn
This article was originally published in The Pink Sheet Daily
Executive Summary
The antithrombin’s efficacy and safety profile suggest ATryn has a clear path to approval.